An amino-acid based diet may help provide relief for patients with eosinophilic gastritis or gastroenteritis (EoG/EoGE), a small prospective study found. All 15 participants experienced a complete ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients on benralizumab had more significant change ...

The good news: a monoclonal antibody treatment called benralizumab proved quite effective in a clinical trial at depleting the number of eosinophils found in the blood and digestive tract tissues of ...

An article published in the journal Gastroenterology & Hepatology highlights recent updates to eosinophilic gastrointestinal disease nomenclature, as well as updates related to diagnosis, pathogenesis ...

Nonspecific clinical symptoms can make identifying eosinophilic gastritis difficult, but detailed examination, biopsy, and testing can rule out other possible causes of eosinophilic infiltration of ...

Benralizumab, an eosinophil-depleting monoclonal antibody, induces histologic remission in patients with eosinophilic gastritis, but persistence of other disease features suggest coexisting eosinophil ...

The good news: a monoclonal antibody treatment called benralizumab proved quite effective in a clinical trial at depleting the number of eosinophils found in the blood and digestive tract tissues of ...

Eosinophilic GI diseases (EGIDs) often overlap with other eosinophil-associated diseases (EADs), which leads to greater health care costs, according to an analysis of the U.S. Optum Clinformatics ...

These rare, chronic relapsing conditions are primarily associated with eosinophilic tissue inflammation. The Food and Drug Administration (FDA) has granted Orphan Drug designations to benralizumab for ...

REDWOOD CITY, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast ...

REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . Patients with food allergies were 15.8 times more likely to develop eosinophilic esophagitis. The prevalence of ...